Advertisement

Issue 19, Volume 127

Cover Figure: Thrombolytic effectiveness of ADAMTS13 in acute ischemic stroke. See the article by Denorme et al.

WASHINGTON, May 12, 2016 – Welcome to “This Week in Blood,” a weekly snapshot of the hottest studies from each week’s issue of Blood, the official journal of the American Society of Hematology (ASH), hand-picked by Blood Editor-in-Chief Bob Löwenberg, MD, PhD, and Deputy Editor Nancy Berliner, MD.

Development and validation of a rapid, aldehyde dehydrogenase bright–based cord blood potency assay
Shoulars and coworkers demonstrate the validity of a novel potency assay for human umbilical cord blood stem cells and its relevance for clinical transplantation practice.

ADAMTS13-mediated thrombolysis of t-PA–resistant occlusions in ischemic stroke in mice
This paper by Denorme and colleagues presents novel findings on the histopathology of patients with ischemic stroke and the thrombolytic effect of recombinant ADAMTS13 on cerebral thrombosis in a mouse model of acute ischemic stroke.

Emerging roles for hemostatic dysfunction in malaria pathogenesis
O'Sullivan et al offer a topical and comprehensive overview of recent research on the emerging role of hemostatic dysfunction in the pathogenesis of severe Plasmodium falciparum malaria.

Anti–factor VIII IgA as a potential marker of poor prognosis in acquired hemophilia A: results from the GTH-AH 01/2010 study
Neutralizing autoantibodies against factor VIII (FVIII) are the cause of acquired hemophilia (AHA). Here, Tiede and colleagues present data to show that anti–FVIII immunoglobulin A represents a potential novel biomarker that could be useful in predicting prognosis and for tailoring immunosuppressive treatment of AHA.

Beyond the plasma cell: emerging therapies for immunoglobulin light chain amyloidosis
In their Blood Spotlight review, Weiss and colleagues explore the challenges of emerging therapies in systemic light chain amyloidosis with a focus on strategies promoting resorption of amyloid deposits.

Limiting hepatic Bmp-Smad signaling by matriptase-2 is required for erythropoietin-mediated hepcidin suppression in mice
Nai and colleagues provide evidence to demonstrate that the serine protease matriptase-2 mediates erythropoietin-dependent expression of hepcidin, a central regulator of iron hemostasis, and has a pathogenetic role in iron-loading diseases.

Differential role of Id1 in MLL-AF9–driven leukemia based on cell of origin
The work by Man et al reveals that the transforming ability of the leukemic fusion oncogene MLL-AF9 is regulated by Id1, a dominant-negative regulator of E protein transcription factors. Their results suggest that Id1 could serve as a potential therapeutic target in a subset of MLL-rearranged leukemias.

 

This week's complete table of contents

Why Submit to Blood?

 

 

Join the "This Week in Blood" mailing list by filling out the form below and clicking Subscribe!
*Email Address:
*First Name:
*Last Name:

 

Blood (www.bloodjournal.org), the most cited peer-reviewed publication in the field of hematology, is available weekly in print and online. Blood is the official journal of the American Society of Hematology (ASH) (www.hematology.org), the world’s largest professional society concerned with the causes and treatment of blood disorders.

ASH’s mission is to further the understanding, diagnosis, treatment, and prevention of disorders affecting blood, bone marrow, and the immunologic, hemostatic, and vascular systems by promoting research, clinical care, education, training, and advocacy in hematology.

blood® is a registered trademark of the American Society of Hematology.